<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00052520</url>
  </required_header>
  <id_info>
    <org_study_id>1655.00</org_study_id>
    <secondary_id>NCI-2009-01471</secondary_id>
    <secondary_id>P01CA018029</secondary_id>
    <nct_id>NCT00052520</nct_id>
  </id_info>
  <brief_title>Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation</brief_title>
  <official_title>Phase I/II Study of Adoptive Immunotherapy With CD8+ WT1-Specific CTL Clones for Patients With Advanced MDS, CML, AML or ALL After Allogeneic Hematopoietic Stem Cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial is studying the side effects of biological therapy and to see how well&#xD;
      it works in treating patients with advanced myelodysplastic syndrome, chronic myeloid&#xD;
      leukemia, acute myeloid leukemia, or acute lymphoblastic leukemia. Biological therapies,&#xD;
      including immunotherapy, can potentially be used to stimulate the immune system and stop&#xD;
      cancer cells from growing. Immunotherapy given to patients who have undergone donor stem cell&#xD;
      transplantation may be a way to eradicate remaining cancer cells&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the safety and potential toxicities associated with infusing donor CD8+&#xD;
      cytotoxic T lymphocyte (CTL) clones specific for Wilms' tumor (WT1) in patients who have&#xD;
      relapsed or at a high risk of relapse post transplant for myelodysplastic syndromes (MDS),&#xD;
      chronic myelogenous leukemia (CML), acute myeloid leukemia (AML), or acute lymphoblastic&#xD;
      leukemia (ALL).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the in vivo persistence of transferred T cells and assess migration to the&#xD;
      bone marrow, a predominant site of leukemic relapse.&#xD;
&#xD;
      II. To determine if adoptively transferred WT1-specific T cells mediate antileukemic&#xD;
      activity.&#xD;
&#xD;
      OUTLINE: Donors undergo leukapheresis for stem cell harvest to generate CD8-positive WT1&#xD;
      gene-specific CTL clones at the time of allogeneic stem cell transplantation.&#xD;
&#xD;
      After post-transplantation hematopoietic recovery, patients receive treatment for either&#xD;
      highest-risk disease (prophylactically) or relapsed disease.&#xD;
&#xD;
      Highest-risk disease group: Patients receive CD8-positive WT1 gene-specific CTL clones&#xD;
      intravenously (IV) over 1-2 hours on days 0, 14, and 28. Beginning 2-4 hours after CTL&#xD;
      infusion, patients receive interleukin-2 subcutaneously (SC) twice daily on days 28-42 in the&#xD;
      absence of unacceptable toxicity.&#xD;
&#xD;
      Relapsed-disease group: Some patients with evidence of leukemic relapse may receive standard&#xD;
      salvage chemotherapy prior to donor CTL infusions and then receive CD8-positive WT1&#xD;
      gene-specific CTL clones and interleukin-2 as in the highest-risk group.&#xD;
&#xD;
      Patients in both groups who have progressive disease after complete or partial response to&#xD;
      therapy may be eligible for retreatment with CD8-positive WT1 gene-specific CTL clones.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity rate associated with infusing donor CD8+ CTL clones specific for WT1 in patients at high risk for post transplant relapse of CML, AML, or ALL</measure>
    <time_frame>Up to 4 weeks after the final dose of CTL</time_frame>
    <description>Assessed by Common Terminology Criteria (CTC) version 3.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse of disease</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Patients achieving complete remission with chemotherapy and T cell infusions will be followed to determine the duration of response. The proportion of responders will be estimated with associated confidence intervals. Duration of remission will be summarized using time-to-event methods, which will allow estimates to be made while some patients remain in remission.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities</condition>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)</condition>
  <condition>B-cell Adult Acute Lymphoblastic Leukemia</condition>
  <condition>B-cell Childhood Acute Lymphoblastic Leukemia</condition>
  <condition>Childhood Chronic Myelogenous Leukemia</condition>
  <condition>Childhood Myelodysplastic Syndromes</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Essential Thrombocythemia</condition>
  <condition>Polycythemia Vera</condition>
  <condition>Previously Treated Myelodysplastic Syndromes</condition>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Recurrent Childhood Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Childhood Acute Myeloid Leukemia</condition>
  <condition>Refractory Anemia With Excess Blasts</condition>
  <condition>Refractory Anemia With Excess Blasts in Transformation</condition>
  <condition>Relapsing Chronic Myelogenous Leukemia</condition>
  <condition>Secondary Acute Myeloid Leukemia</condition>
  <condition>T-cell Adult Acute Lymphoblastic Leukemia</condition>
  <condition>T-cell Childhood Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>ALLOLYMPH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>IL-2</other_name>
    <other_name>Proleukin</other_name>
    <other_name>recombinant human interleukin-2</other_name>
    <other_name>recombinant interleukin-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Undergo transplantation</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSC transplantation</other_name>
    <other_name>peripheral blood progenitor cell transplantation</other_name>
    <other_name>transplantation, peripheral blood stem cell</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
    <description>Undergo transplantation</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>bone marrow therapy, allogeneic</other_name>
    <other_name>bone marrow therapy, allogenic</other_name>
    <other_name>transplantation, allogeneic bone marrow</other_name>
    <other_name>transplantation, allogenic bone marrow</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunologic technique</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>immunological laboratory methods</other_name>
    <other_name>laboratory methods, immunological</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>PCR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>cytogenetic analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>staining method</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Staining</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eligibility for Enrollment:&#xD;
&#xD;
               -  a.&#xD;
&#xD;
                    -  i) Pre-transplant: Patients undergoing allogeneic hematopoietic stem cell&#xD;
                       transplantation for refractory anemia with excess blasts (RAEB), refractory&#xD;
                       anemia with excess blasts in transformation (RAEB-t), CML beyond chronic&#xD;
                       phase, AML beyond first remission, Philadelphia chromosome&#xD;
                       (BCR-ABL)-positive ALL at any stage, any ALL beyond first remission, primary&#xD;
                       refractory AML or ALL, therapy-related AML at any stage, or acute leukemia&#xD;
                       at any stage arising in a patient with an antecedent diagnosis of a&#xD;
                       myelodysplastic or myeloproliferative syndrome (including chronic&#xD;
                       myelomonocytic leukemia, CML, polycythemia vera, essential thrombocytosis,&#xD;
                       and agnogenic myeloid metaplasia with myelofibrosis);&#xD;
&#xD;
                    -  ii) Post-transplant: Patients who have relapsed after transplant&#xD;
                       (morphologic, flow cytometric, cytogenetic and molecular relapse) can be&#xD;
                       offered enrollment on the protocol and may undergo therapy if it is&#xD;
                       considered possible to control their disease while waiting for the&#xD;
                       generation of study therapy&#xD;
&#xD;
               -  b. Patients and donors must both express an human leukocyte antigen (HLA)-allele&#xD;
                  for which it is possible to generate WT1-specific clones for&#xD;
&#xD;
               -  c. Patients must be able to provide blood and bone marrow samples required for&#xD;
                  this protocol&#xD;
&#xD;
          -  Eligibility for Prophylactic Treatment with CD8+ CTL After Transplant (Highest Risk&#xD;
             Subgroup): At time of planned treatment, CD8+ CTL specific for WT1 must have been&#xD;
             generated and have completed Quality Control (QC) testing&#xD;
&#xD;
               -  a. Patients must have had &gt; 5% morphologic blasts detectable in bone marrow or&#xD;
                  peripheral blood just prior to or at the time of transplant&#xD;
&#xD;
               -  b. Patients must have evidence of post transplant recovery of normal&#xD;
                  hematopoiesis (absolute neutrophil count [ANC] &gt; 500/mm^3) for at least 7 days&#xD;
                  prior to the initiation of CTL infusions&#xD;
&#xD;
               -  c. Patients on immunosuppressive therapy for graft-versus-host disease (GVHD) are&#xD;
                  eligible for treatment if not receiving corticosteroids or if the dose of&#xD;
                  corticosteroids can be tapered to =&lt; the equivalent of 0.5 mg/kg/day of&#xD;
                  prednisone; the patient's symptoms have to remain stable and unlikely to increase&#xD;
                  to stage III or IV acute GVHD or chronic GVHD is unlikely to progress following&#xD;
                  the change in immunosuppressive therapy, after an appropriate monitoring period,&#xD;
                  as deemed by the patients treating physician and the principal investigator&#xD;
&#xD;
          -  Eligibility for Treatment with CD8+ CTL at the Time of Relapse after Transplant (All&#xD;
             Others): At time of planned treatment, CD8+ CTL specific for WT1 must have been&#xD;
             generated and have completed Quality Control (QC) testing&#xD;
&#xD;
               -  a. Patients must have evidence of recurrent disease post transplant; this&#xD;
                  includes patients with the following:&#xD;
&#xD;
                    -  i) Morphologic relapse defined as one or more of the following: Abnormal&#xD;
                       peripheral blasts in absence of growth factor therapy; abnormal bone marrow&#xD;
                       blasts &gt; 5% of nucleated cells; extramedullary chloroma or granulocytic&#xD;
                       sarcoma&#xD;
&#xD;
                    -  ii) Flow cytometric relapse defined as: the appearance in the peripheral&#xD;
                       blood or bone marrow of cells with an abnormal; immunophenotype detected by&#xD;
                       flow cytometry that is consistent with leukemia recurrence&#xD;
&#xD;
                    -  iii) Cytogenetic relapse defined as: the appearance in one or more&#xD;
                       metaphases from bone marrow or peripheral blood cells of either a&#xD;
                       non-constitutional cytogenetic abnormality identified in at least one&#xD;
                       cytogenetic study performed prior to transplant or a new abnormality known&#xD;
                       to be associated with leukemia; (for CML) an increase in the number of Ph+&#xD;
                       metaphases from bone marrow or peripheral blood between two consecutive&#xD;
                       samples after engraftment, or; an increase in the percentage of BCR/ABL+&#xD;
                       cells by fluorescence in situ hybridization (FISH) between two consecutive&#xD;
                       samples after engraftment&#xD;
&#xD;
                    -  iv) Molecular relapse defined as: one or more positive polymerase chain&#xD;
                       reaction (PCR) assays for the presence of clonotypic immunoglobulin heavy&#xD;
                       chain (IgH) or T cell receptor (TCR) gene rearrangement in patients&#xD;
                       transplanted for B-or T-cell acute lymphoblastic leukemia, respectively; one&#xD;
                       or more positive post transplant reverse transcription (RT)-PCR assays for&#xD;
                       the presence of BCR-ABL messenger ribonucleic acid (mRNA) fusion transcripts&#xD;
                       in patients transplanted for Philadelphia chromosome (BCRABL)-positive acute&#xD;
                       lymphoblastic leukemia; (for CML) a PCR assay of bone marrow (BM) or&#xD;
                       peripheral blood mononuclear cell (PBMC) positive for the presence of the&#xD;
                       BCR/ABL mRNA fusion transcript that quantitatively increases by greater than&#xD;
                       one order of magnitude on a subsequent sample&#xD;
&#xD;
               -  b. Patients on immunosuppressive therapy for GVHD at the time of relapse are&#xD;
                  eligible for treatment if not receiving corticosteroids or if the dose of&#xD;
                  corticosteroids can be tapered to &lt; the equivalent of 0.5 mg/kg/day of&#xD;
                  prednisone; the patient's symptoms have to remain stable and unlikely to increase&#xD;
                  to stage III or IV acute GVHD or chronic GVHD is unlikely to progress following&#xD;
                  the change in immunosuppressive therapy, after an appropriate monitoring period,&#xD;
                  as deemed by the patients treating physician and the principal investigator&#xD;
&#xD;
          -  DONOR: Both the patient and donor must have an HLA-allele which it is possible to&#xD;
             generate WT1-specific clones for&#xD;
&#xD;
          -  DONOR: If a separate leukapheresis via peripheral intravenous access can be arranged,&#xD;
             the stem cell donor will undergo leukapheresis to provide the required PBMC no sooner&#xD;
             than 2 weeks before or after the stem cell mobilization and harvest&#xD;
&#xD;
          -  DONOR: If a separate leukapheresis is not possible, a portion of the PBMC from the&#xD;
             donor's peripheral blood stem cell harvest may potentially be used to generate&#xD;
             WT1-specific CTL clones; the feasibility of this option will depend upon the minimal&#xD;
             cell dose required for transplantation and the presence of an excess harvest yield and&#xD;
             the possibility of generating CTL from this product&#xD;
&#xD;
          -  DONOR: Some donors will be asked to provide both a separate leukapheresis and a&#xD;
             portion of the peripheral blood mononuclear cells (PBMC) from the donor's peripheral&#xD;
             blood stem cell harvest&#xD;
&#xD;
          -  DONOR: Leukapheresis donors must be age 18 or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients for whom CD8+ CTL clones specific for WT1 have not been generated in time for&#xD;
             planned infusion (these patients can potentially be treated later if CTL become&#xD;
             available); Also we will exclude patients whose malignant cells do not over express&#xD;
             WT-1, based on direct analysis of a bone marrow sample with &gt; 50% blasts or of&#xD;
             leukemia cells isolated for expression analysis; in either case patients will be&#xD;
             informed about the availability of other treatment protocols for which they might be&#xD;
             eligible&#xD;
&#xD;
          -  Patients with Karnofsky performance status or Lansky play score =&lt; 30%&#xD;
&#xD;
          -  Patients with current stage III or IV GVHD unresponsive to therapy or requiring&#xD;
             therapy with anti-CD3 mAb, prednisone &gt; 0.5 mg/kg/day (or corticosteroid equivalent),&#xD;
             or other treatments resulting in the ablation or inactivation of T cells (such as&#xD;
             other anti-T cell monoclonal antibodies); although the concurrent use of cyclosporine,&#xD;
             FK506, or MMF is not strictly an exclusion criteria, attempts should be made to&#xD;
             discontinue it if possible&#xD;
&#xD;
          -  Patients requiring concurrent therapy with hydroxyurea or other agents that may&#xD;
             interfere with the function or survival of infused CTL clones&#xD;
&#xD;
          -  Patients with a preexisting nonhematopoietic organ toxicity that is deemed by the&#xD;
             principal investigator to place the patient at unacceptable risk for treatment on the&#xD;
             protocol&#xD;
&#xD;
          -  Patients with graft rejection or failure&#xD;
&#xD;
          -  DONOR: Medical conditions precluding either leukapheresis or blood donation may&#xD;
             include but are not limited to:&#xD;
&#xD;
               -  Inadequate age or weight (leukapheresis donors must be age 18 or older, other&#xD;
                  criteria per physician discretion)&#xD;
&#xD;
               -  Active infection, with or without antibiotic treatment&#xD;
&#xD;
               -  Recent hepatitis exposure, hepatitis A or B antigenemia, or hepatitis C antibody&#xD;
                  positivity&#xD;
&#xD;
               -  Pregnancy or nursing; HIV or human T-lymphotropic virus (HTLV) infection&#xD;
&#xD;
               -  Severe cardiovascular disease (e.g., uncontrolled hypertension, recent myocardial&#xD;
                  infarction [MI], or unstable angina)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merav Bar</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>January 24, 2003</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <disposition_first_submitted>March 27, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>March 27, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 29, 2017</disposition_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fred Hutchinson Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Merav Bar</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Anemia, Refractory</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
    <mesh_term>Anemia, Refractory, with Excess of Blasts</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

